Although uveitis after vaccination is rare, reports emerged during the COVID-19 pandemic. We used the pharmacovigilance case/non-case study from 1967 to 2023 to assess the association between vaccines and uveitis. We identified a significant signal for uveitis (reporting OR (ROR), 1.64; information component (IC)025, 0.66) with 1508 reports. This association is pronounced in females of all ages after childhood. Specifically, the COVID-19 messenger RNA vaccines showed the strongest disproportionality signal (ROR, 5.76; IC025, 2.33), followed by hepatitis B, papillomavirus, Ad (Adenovirus) 5-vectored COVID-19 and influenza vaccines. These findings underscore the importance of surveillance in the postmarketing phase to manage potential adverse events associated with vaccine administration. The data are available upon request. Study protocol and statistical code: Available from DKY (yonkkang@gmail.com). Data set: Available from the Uppsala Monitoring Centre or WHO through a data use agreement.

中文翻译：

---

1967-2023 年疫苗相关葡萄膜炎及其相关疫苗的全球负担


虽然接种疫苗后葡萄膜炎很少见，但在 COVID-19 大流行期间出现了报告。我们使用 1967 年至 2023 年的药物警戒病例/非案例研究来评估疫苗与葡萄膜炎之间的关联。我们确定了葡萄膜炎的重要信号 （报告 OR （ROR），1.64;信息成分 （IC）025,0.66），有 1508 份报告。这种关联在童年后的所有年龄段的女性中都很明显。具体来说，COVID-19 信使 RNA 疫苗显示出最强的不成比例信号（ROR，5.76;IC025， 2.33），其次是乙型肝炎、瘤病毒、Ad（腺病毒）5 载体 COVID-19 和流感疫苗。这些发现强调了上市后阶段监测对管理与疫苗接种相关的潜在不良事件的重要性。数据可应要求提供。研究方案和统计代码：可从 DKY （yonkkang@gmail.com） 获得。数据集：通过数据使用协议从乌普萨拉监测中心或 WHO 获得。